Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.02
(4.18%)
SEK 0.02
(4.18%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 23 Thousand | 203 Thousand | 407 Thousand | 20.31 Thousand |
| Cost of Revenue | -3.11 Million | -1.85 Million | 492 Thousand | 627.86 Thousand |
| Gross Profit | 3.13 Million | 2.05 Million | -85 Thousand | -607.55 Thousand |
| Operating Expenses | 14.7 Million | 17.21 Million | 11.57 Million | 708 Thousand |
| Selling, General and Administrative Expenses | 14.67 Million | 17.22 Million | 7.1 Million | 740 Thousand |
| Research and Development Expenses | - | - | - | - |
| Other Expenses | 23 Thousand | 17.21 Million | 4.47 Million | - |
| Cost and Expenses | 11.58 Million | 15.36 Million | 12.07 Million | 627.86 Thousand |
| Operating Income | -11.56 Million | -15.16 Million | -11.66 Million | -607.55 Thousand |
| Interest Expense | 206 Thousand | 1 Million | - | - |
| Income Tax Expense | - | -15.16 Million | -11.69 Million | - |
| Earnings before Tax | -11.67 Million | -16.16 Million | -11.66 Million | -583.36 Thousand |
| Net Income | -11.67 Million | -16.16 Million | -11.66 Million | -583.36 Thousand |
| Earnings Per Share Basic | -0.32 | -1.70 | -1.70 | -0.17 |
| Earnings Per Share Diluted | -0.32 | -1.70 | -1.70 | -0.17 |
| Weighted Average Shares Outstanding | 36.47 Million | 9.49 Million | 6.87 Million | 3.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 36.47 Million | 9.49 Million | 6.87 Million | 3.5 Million |
| Gross Margin | 136.22 | 10.12 | -0.21 | -29.91 |
| EBIT Margin | -498.65 | -74.69 | -28.66 | 8.36 |
| Profit Margin | -507.74 | -79.63 | -28.66 | -28.72 |
| EBITDA | -11.46 Million | - | -11.66 Million | 193.97 Thousand |
| Earnings Before Tax Margin | -502.87 | -74.69 | -28.66 | -29.91 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | 284 Thousand | 250 Thousand | 23 Thousand | 23 Thousand | 781 Thousand |
| Cost of Revenue | 314 Thousand | 354 Thousand | -250 Thousand | 2.47 Million | 11.56 Million | -790 Thousand |
| Gross Profit | -314 Thousand | -70 Thousand | 500 Thousand | -2.45 Million | -11.54 Million | 1.57 Million |
| Operating Expenses | 928 Thousand | 2.76 Million | 2.97 Million | 2.87 Million | 14.7 Million | 3.39 Million |
| Selling, General and Administrative Expenses | 928 Thousand | 2.76 Million | 2.97 Million | 2.86 Million | - | 2.59 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | 202 Thousand | - | - | - | - |
| Cost and Expenses | 1.24 Million | 3.11 Million | 2.72 Million | 2.47 Million | 11.56 Million | 2.6 Million |
| Operating Income | -1.24 Million | -3.11 Million | -2.72 Million | -2.45 Million | -11.54 Million | -2.6 Million |
| Interest Expense | - | 322 Thousand | 262 Thousand | 154 Thousand | 206 Thousand | 52 Thousand |
| Income Tax Expense | 1000.00 | - | -41.27 Thousand | -41.81 Thousand | -164.89 Thousand | -1000.00 |
| Earnings before Tax | -1.24 Million | -3.44 Million | -2.98 Million | -2.53 Million | -11.67 Million | -2.65 Million |
| Net Income | -1.24 Million | -3.44 Million | -2.98 Million | -2.53 Million | -11.67 Million | -2.65 Million |
| Earnings Per Share Basic | -0.00 | -0.01 | -0.07 | -0.06 | - | -0.08 |
| Earnings Per Share Diluted | -0.00 | -0.01 | -0.07 | -0.06 | - | -0.08 |
| Weighted Average Shares Outstanding | 400.63 Million | 280.42 Million | 39.97 Million | 39.61 Million | 60.19 Million | 34.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 400.63 Million | 280.41 Million | 39.97 Million | 39.61 Million | 60.19 Million | 34.76 Million |
| Gross Margin | - | -0.25 | 2.00 | -106.70 | -502.00 | 2.01 |
| EBIT Margin | - | -9.73 | -10.90 | -106.61 | - | -3.34 |
| Profit Margin | - | -12.11 | -11.96 | -110.00 | -507.74 | -3.40 |
| EBITDA | -927 Thousand | -2.76 Million | -2.72 Million | -2.45 Million | - | -2.6 Million |
| Earnings Before Tax Margin | - | -10.98 | -10.91 | -106.70 | -502.00 | -3.34 |
GENPHARMA
GATE
SPOI
QBAT
HBIE
032350